Hip Replacement Liners for Osteoarthritis
Trial Summary
What is the purpose of this trial?
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the G7 Acetabular System and related components for hip replacement in osteoarthritis?
Research on dual mobility systems, which are part of the G7 Acetabular System, shows they can provide greater stability and a wide range of motion, which are beneficial for hip replacements. However, there are concerns about wear and dislocation rates, with some studies indicating that these systems may not significantly reduce wear compared to conventional systems.12345
Is the G7 Acetabular System and similar hip replacement liners safe for humans?
The G7 Acetabular System and similar hip replacement liners, like dual mobility systems, have shown potential advantages in reducing dislocation rates, but there are concerns about complications such as intraprosthetic dislocation and metal ion release. These issues suggest that while they can be beneficial, they should be used carefully, especially in younger patients.16789
What makes the G7 Acetabular System treatment unique for hip replacement in osteoarthritis?
Research Team
Hillary Overholser
Principal Investigator
Zimmer Biomet
Eligibility Criteria
This trial is for adults with full skeletal maturity who need hip replacement due to conditions like osteoarthritis or fractures. Candidates must be able to follow the study protocol and attend follow-up visits. Pregnant individuals, those with bone formation disorders, severe osteoporosis, infections that could affect the implant site, substance abuse issues, or unmanageable neuromuscular diseases cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Implantation of the G7 Acetabular Shells with Vivacit-E or Longevity HXLPE liners in primary and revision total hip arthroplasty
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of implant survival and adverse events
Long-term follow-up
Continued monitoring of patient-reported outcomes and quality of life measures
Treatment Details
Interventions
- G7 Acetabular System
- Vivacit-E and Longevity (HXLPE) Liners
G7 Acetabular System is already approved in European Union, United States for the following indications:
- Non-inflammatory degenerative joint disease
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement
- Revision procedures where other treatment or devices have failed
- Non-inflammatory degenerative joint disease
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement
- Revision procedures where other treatment or devices have failed
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business